Prognostic value of peripheral blood mononuclear cell-associated HIV-1 DNA for virological outcome in asymptomatic HIV-1 chronic infection

Journal of Clinical Virology

Volumn 48, Issue 3, 2010, Pages 168-172

  Rodríguez Sáinz, Carmen ^a   Ramos, Ricardo ^b   Valor, Lara ^a   López, Francisco ^c   Santamaría, Beatriz ^a   Hernández, Diana C ^a   Cruz, Joana S P ^b   Navarro, Joaquín ^a   Modrego, Jara ^a   Alecsandru, Diana ^a   Fernández Cruz, Eduardo ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b Laboratorio de Cuantificación Génica   (Spain)

^c Department Statistics ^*  (Spain)

Author keywords

Asymptomatic HIV 1 chronic infection; HIV 1 reservoir; HIV 1 RNA viremia; PBMC HIV 1 DNA; Prognostic marker; Therapeutic vaccination

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNIZATION; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

BLOOD; CD4 LYMPHOCYTE COUNT; DNA, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RNA, VIRAL; TREATMENT OUTCOME; VIROLOGY;

EID: 77953229442     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2010.03.020     Document Type: Article

References (51)

1. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5 5 (1999) 512-517
2. Siliciano J.D., Kajdas J., Finzi D., Quinn T.C., Chadwick K., Margolick J.B., et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9 6 (2003) 727-728
3. Sedaghat A.R., Siliciano R.F., and Wilke C.O. Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART. BMC Infect Dis 8 (2008) 2
4. Chun T.W., Justement J.S., Moir S., Hallahan C.W., Maenza J., Mullins J.I., et al. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis 195 12 (2007) 1762-1764
5. Strain M.C., Günthard H.F., Havlir D.V., Ignacio C.C., Smith D.M., Leigh-Brown A.J., et al. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci USA 100 8 (2003) 4819-4824
6. Strain M.C., Little S.J., Daar E.S., Havlir D.V., Gunthard H.F., Lam R.Y., et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 191 9 (2005) 1410-1418
7. Pomerantz R.J. Reservoirs, sanctuaries, and residual disease: the hiding spots of HIV-1. HIV Clin Trials 4 2 (2003) 137-143
8. Maldarelli F., Palmer S., and King M.S. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 3 4 (2007) e46
9. Chun T.W., Nickle D.C., Justement J.S., Meyers J.H., Roby G., Hallahan C.W., et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 197 5 (2008) 714-720
10. Gallo R.C. The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years. Lancet 366 9500 (2005) 1894-1898
11. Pierson T., McArthur J., and Siliciano R.F. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol 18 (2000) 665-708
12. Blankson J.N., Persaud D., and Siliciano R.F. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 53 (2002) 557-593
13. Alexaki A., Liu Y., and Wigdahl B. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res 6 5 (2008) 388-400
14. Hughes M.D., Johnson V.A., Hirsch M.S., Bremer J.W., Elbeik T., Erice A., et al. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response, ACTG 241 Protocol Virology Substudy Team. Ann Intern Med 126 12 (1997) 929-938
15. O'Brien W.A., Hartigan P.M., Martin D., Esinhart J., Hill A., Benoit S., et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med 334 7 (1996) 426-431
16. O'Brien W.A., Hartigan P.M., Daar E.S., Simberkoff M.S., and Hamilton J.D. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS. Ann Intern Med 126 12 (1997) 939-945
17. Katzenstein D.A., Hammer S.M., Hughes M.D., Gundacker H., Jackson J.B., Fiscus S., et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 335 15 (1996) 1091-1098
18. Kempf D.J., Rode R.A., Xu Y., Sun E., Heath-Chiozzi M.E., Valdes J., et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 12 5 (1998) F9-14
19. Powderly W.G., Saag M.S., Chapman S., Yu G., Quart B., and Clendeninn N.J. Predictors of optimal virological response to potent antiretroviral therapy. AIDS 13 14 (1999) 1873-1880
20. Swindells S., Evans S., Zackin R., Goldman M., Haubrich R., Filler S.G., et al. Predictive value of HIV-1 viral load on risk for opportunistic infection. J Acquir Immune Defic Syndr 30 2 (2002) 154-158
21. Ferre F., Moss R.B., Daigle A., Richieri S.P., Jensen F., and Carlo D.J. Viral load in peripheral blood mononuclear cells as surrogate for clinical progression. J Acquir Immune Defic Syndr Hum Retrovirol 10 Suppl. 2 (1995) S51-S56
22. Verhofstede C., Reniers S., Van Wanzeele F., and Plum J. Evaluation of proviral copy number and plasma RNA level as early indicators of progression in HIV-1 infection: correlation with virological and immunological markers of disease. AIDS 8 10 (1994) 1421-1427
23. Russell R.R., Bowmer M.I., Nguyen C., and Grant M.D. HIV-1 DNA burden in peripheral blood CD4+ cells influences disease progression, antiretroviral efficacy, and CD4+ T-cell restoration. Viral Immunol 14 4 (2001) 379-389
24. Rouzioux C., Hubert J.B., Burgard M., Deveau C., Goujard C., Bary M., et al. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis 192 1 (2005) 46-55
25. Goujard C., Bonarek M., Meyer L., Bonnet F., Chaix M.L., Deveau C., et al. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis 42 5 (2006) 709-715
26. Ngo-Giang-Huong N., Deveau C., Da Silva I., Pellegrin I., Venet A., Harzic M., et al. Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy. AIDS 15 6 (2001) 665-673
27. Kostrikis L.G., Touloumi G., Karanicolas R., Pantazis N., Anastassopoulou C., Karafoulidou A., et al. Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load. J Virol 76 20 (2002) 10099-10108
28. Hatzakis A.E., Touloumi G., Pantazis N., Anastassopoulou C.G., Katsarou O., Karafoulidou A., et al. Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy. AIDS 18 17 (2004) 2261-2267
29. Tierney C., Lathey J.L., Christopherson C., Bettendorf D.M., D'Aquila R.T., Hammer S., et al. Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy. J Infect Dis 187 (2003) 44-48
30. Re M.C., Vitone F., Bon I., Schiavone P., and Gibellini D. Meaning of DNA detection during the follow-up of HIV-1 infected patients: a brief review. New Microbiol 29 2 (2006) 81-88
31. Saitoh A., Hsia K., Fenton T., Powell C.A., Christopherson C., Fletcher C.V., et al. Persistence of human immunodeficiency virus type I DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children. J Infect Dis 185 10 (2002) 1409-1416
32. Minga A.K., Anglaret X., d'Aquin Toni T., Chaix M.L., Dohoun L., Abo Y., et al. HIV-1 DNA in peripheral blood mononuclear cells is strongly associated with HIV-1 disease progression in recently infected West African adults. J Acquir Immune Defic Syndr 48 (2008) 350-354
33. Avettand-Feoel V., Boufassa F., Galimand J., Meyer L., and Rouzioux C. HIV-1 DNA for measurement of the HIV reservoir is predictive of disease progression in seroconverters whatever the mode of result expression is. J Clin Virol 42 (2008) 399-404
34. Fernandez-Cruz E., Moreno S., Navarro J., Clotet B., Bouza E., Carbone J., et al. Therapeutic immunization with an inactivated HIV-1 immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects. Vaccine 22 23-24 (2004) 2966-2973
35. Valor L., Navarro J., Carbone J., Rodríguez-Sáinz C., Gil J., López F., et al. Immunization with an HIV-1 immunogen induces CD4+ and CD8+ HIV-1-specific polyfunctional responses in patients with chronic HIV-1 infection receiving antiretroviral therapy. Vaccine 26 22 (2008) 2738-2745
36. Gibellini D., Vitone F., Schiavone P., Ponti C., La Placa M., and Re M.C. Quantitative detection of human immunodeficiency virus type 1 (HIV-1) proviral DNA in peripheral blood mononuclear cells by SYBR green real-time PCR technique. J Clin Virol 29 4 (2004) 282-289
37. Grambsch P., and Therneau T. Proportional hazards tests and diagnostics based on weighted residual. Biometrika 81 (1994) 515-526
38. Désiré N., Dehée A., Schneider V., Jacomet C., Goujon C., Girard P.M., et al. Quantification of human immunodeficiency virus type 1 proviral load by a TaqMan real-time PCR assay. J Clin Microbiol 39 4 (2001) 303-310
39. Carr J.M., Cheney K.M., Coolen C., Davis A., Shaw D., Ferguson W., et al. Development of methods for coordinate measurement of total cell-associated and integrated human immunodeficiency virus type 1 (HIV-1) DNA forms in routine clinical samples: levels are not associated with clinical parameters, but low levels of integrated HIV-1 DNA may be prognostic for continued successful therapy. J Clin Microbiol 45 4 (2007) 1288-1297
40. ® real-time PCR. BMC Infect Dis 5 (2005) 5
41. Chun T.W., Carruth L., Finzi D., Shen X., DiGiuseppe J.A., Taylor H., et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387 6629 (1997) 183-188
42. Hermankova M., Siliciano J.D., Zhou Y., Monie D., Chadwick K., Margolick J.B., et al. Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol 77 13 (2003) 7383-7392
43. Zhou Y., Zhang H., Siliciano J.D., and Siliciano R.F. Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells. J Virol 79 4 (2005) 2199-2210
44. Chun T.W., Justement J.S., Lempicki R.A., Yang J., Dennis Jr. G., Hallahan C.W., et al. Gene expression and viral production in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc Natl Acad Sci USA 100 4 (2003) 1908-1913
45. Zhu T., Muthui D., Holte S., Nickle D., Feng F., Brodie S., et al. Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J Virol 76 2 (2002) 707-716
46. Almodóvar S., Del C., Colón M., Maldonado I.M., Villafañe R., Abreu S., et al. HIV-1 infection of monocytes is directly related to the success of HAART. Virology 369 1 (2007) 35-46
47. Gibellini D., Borderi M., De Crignis E., Cicola R., Cimatti L., Vitone F., et al. HIV-1 DNA load analysis in peripheral blood lymphocytes and monocytes from naïve and HAART-treated individuals. J Infect 56 3 (2008) 219-225
48. Bugard M., Boufassa F., Viard J.P., Garrigue I., Ruffault A., Izopet J., et al. Factors influencing peripheral blood mononuclear cell-associated HIV-1 DNA level after long-term suppressive antiretroviral therapy in 236 patients. AIDS 23 (2009) 2165-2171
49. Blankson J.N., Finzi D., Pierson T.C., Sabundayo B.P., Chadwick K., Margolick J.B., et al. Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection. J Infect Dis 182 (2000) 1636-1642
50. Perelson A.S., Essunger P., Cao Y., Vesanen M., Hurley A., Saksela K., et al. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature 387 (1997) 88-91
51. Koelsch K.K., Liu L., Haubrich R., May S., Havlir D., Günthard H.F., et al. Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis 197 3 (2008) 11-19